Haimiao Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Haimiao Xu has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Carl Michael Gay
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
30 shared publications - Dan Su
Tencent AI Lab Tencent Shenzhen China
30 shared publications Dapeng Zhu
30 shared publications- Huan Deng
Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
30 shared publications - Huarong Tang
16Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China
30 shared publications Jinshi Liu
30 shared publications
Latest Publications
- Open Access
- 6 February 2024
- Published by Springer Nature in npj Precision Oncology
- Vol. 8 (1) , 1-12
Single-cell low-pass whole genome sequencing accurately detects circulating tumor cells for liquid biopsy-based multi-cancer diagnosis
Accurate detection of circulating tumor cells (CTCs) in blood and non-blood body fluids enables generation of deterministic cancer diagnosis and represent a less invasive and safer liquid biopsy approach. Although genomic alternations have been widely used in circulating tumor DNA (ctDNA) analysis, studies on cell-based genomic alternations profiling for CTC detection are rare due to major technical limitations in single-cell whole genome sequencing (WGS) including low throughput, low accuracy and high cost. We report a single-cell low-pass WGS-based protocol (scMet-Seq) for sensitive and accurate CTC detection by combining a metabolic function-associated marker Hexokinase 2 (HK2) and a Tn5 transposome-based WGS method with improved cell fixation strategy. To explore the clinical use, scMet-Seq has been investigated with blood and non-blood body fluids in diagnosing metastatic diseases, including ascites-based diagnosis of malignant ascites (MA) and blood-based diagnosis of metastatic small-cell lung cancer (SCLC). ScMet-Seq shows high diagnostic sensitivity (MA: 79% in >10 cancer types; metastatic SCLC: 90%) and ~100% of diagnostic specificity and positive predictive value, superior to clinical cytology that exhibits diagnostic sensitivity of 52% in MA diagnosis and could not generate blood-based diagnosis. ScMet-Seq represents a liquid biopsy approach for deterministic cancer diagnosis in different types of cancers and body fluids.
- 6 February 2024
- Published by Springer Nature in npj Precision Oncology
- Vol. 8 (1) , 1-12
Open AccessSingle-cell low-pass whole genome sequencing accurately detects circulating tumor cells for liquid biopsy-based multi-cancer diagnosis
Accurate detection of circulating tumor cells (CTCs) in blood and non-blood body fluids enables generation of deterministic cancer diagnosis and represent a less invasive and safer liquid biopsy approach. Although genomic alternations have been widely used in circulating tumor DNA (ctDNA) analysis, studies on cell-based genomic alternations profiling for CTC detection are rare due to major technical limitations in single-cell whole genome sequencing (WGS) including low throughput, low accuracy and high cost. We report a single-cell low-pass WGS-based protocol (scMet-Seq) for sensitive and accurate CTC detection by combining a metabolic function-associated marker Hexokinase 2 (HK2) and a Tn5 transposome-based WGS method with improved cell fixation strategy. To explore the clinical use, scMet-Seq has been investigated with blood and non-blood body fluids in diagnosing metastatic diseases, including ascites-based diagnosis of malignant ascites (MA) and blood-based diagnosis of metastatic small-cell lung cancer (SCLC). ScMet-Seq shows high diagnostic sensitivity (MA: 79% in >10 cancer types; metastatic SCLC: 90%) and ~100% of diagnostic specificity and positive predictive value, superior to clinical cytology that exhibits diagnostic sensitivity of 52% in MA diagnosis and could not generate blood-based diagnosis. ScMet-Seq represents a liquid biopsy approach for deterministic cancer diagnosis in different types of cancers and body fluids.
- Open Access
- 15 June 2023
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 102 (8) , 1026-1033
Assessing artificial intelligence enabled liquid‐based cytology for triaging HPV‐positive women: a population‐based cross‐sectional study
Introduction: Cytology‐based triaging is commonly used to manage the care of women with positive human papillomavirus (HPV) results, but it suffers from subjectivity and a lack of sensitivity and reproducibility. The diagnostic performance of an artificial intelligence‐enabled liquid‐based cytology (AI‐LBC) triage approach remains unclear. Here, we compared the clinical performance of AI‐LBC, human cytologists and HPV16/18 genotyping at triaging HPV‐positive women.Material and methods: HPV‐positive women were triaged using AI‐LBC, human cytologists and HPV16/18 genotyping. Histologically confirmed cervical intraepithelial neoplasia grade 2/3 or higher (CIN2+/CIN3+) were accepted as thresholds for clinical performance assessments.Results: Of the 3514 women included, 13.9% (n = 489) were HPV‐positive. The sensitivity of AI‐LBC was comparable to that of cytologists (86.49% vs 83.78%, P = 0.744) but substantially higher than HPV16/18 typing at detecting CIN2+ (86.49% vs 54.05%, P = 0.002). While the specificity of AI‐LBC was significantly lower than HPV16/18 typing (51.33% vs 87.17%, P < 0.001), it was significantly higher than cytologists at detecting CIN2+ (51.33% vs 40.93%, P < 0.001). AI‐LBC reduced referrals to colposcopy by approximately 10%, compared with cytologists (51.53% vs 60.94%, P = 0.003). Similar patterns were also observed for CIN3+.Conclusions: AI‐LBC has equivalent sensitivity and higher specificity compared with cytologists, with more efficient colposcopy referrals for HPV‐positive women. AI‐LBC could be particularly useful in regions where experienced cytologists are few in number. Further investigations are needed to determine triaging performance through prospective designs.
- 15 June 2023
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 102 (8) , 1026-1033
Open AccessAssessing artificial intelligence enabled liquid‐based cytology for triaging HPV‐positive women: a population‐based cross‐sectional study
Introduction: Cytology‐based triaging is commonly used to manage the care of women with positive human papillomavirus (HPV) results, but it suffers from subjectivity and a lack of sensitivity and reproducibility. The diagnostic performance of an artificial intelligence‐enabled liquid‐based cytology (AI‐LBC) triage approach remains unclear. Here, we compared the clinical performance of AI‐LBC, human cytologists and HPV16/18 genotyping at triaging HPV‐positive women.Material and methods: HPV‐positive women were triaged using AI‐LBC, human cytologists and HPV16/18 genotyping. Histologically confirmed cervical intraepithelial neoplasia grade 2/3 or higher (CIN2+/CIN3+) were accepted as thresholds for clinical performance assessments.Results: Of the 3514 women included, 13.9% (n = 489) were HPV‐positive. The sensitivity of AI‐LBC was comparable to that of cytologists (86.49% vs 83.78%, P = 0.744) but substantially higher than HPV16/18 typing at detecting CIN2+ (86.49% vs 54.05%, P = 0.002). While the specificity of AI‐LBC was significantly lower than HPV16/18 typing (51.33% vs 87.17%, P < 0.001), it was significantly higher than cytologists at detecting CIN2+ (51.33% vs 40.93%, P < 0.001). AI‐LBC reduced referrals to colposcopy by approximately 10%, compared with cytologists (51.53% vs 60.94%, P = 0.003). Similar patterns were also observed for CIN3+.Conclusions: AI‐LBC has equivalent sensitivity and higher specificity compared with cytologists, with more efficient colposcopy referrals for HPV‐positive women. AI‐LBC could be particularly useful in regions where experienced cytologists are few in number. Further investigations are needed to determine triaging performance through prospective designs.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Figure S3Mutational signatures. The mutational signatures in treatment-naïve and relapsed samples are presented in (A) and (B), respectively.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Figure S3Mutational signatures. The mutational signatures in treatment-naïve and relapsed samples are presented in (A) and (B), respectively.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S6 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Figure S6Differentially expressed proteins between the chemo-resistant and chemo-sensitive SCLCs by MS based proteomics. A1, A2, A3 represents chemo-resistant samples; B1, B2, B3 represents chemo-sensitive samples. Genes which have previously been reported to be associated with drug resistance are colored by red. The foldchange: average expression in A group / average expression in B group. MS: mass spectrum.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Figure S6Differentially expressed proteins between the chemo-resistant and chemo-sensitive SCLCs by MS based proteomics. A1, A2, A3 represents chemo-resistant samples; B1, B2, B3 represents chemo-sensitive samples. Genes which have previously been reported to be associated with drug resistance are colored by red. The foldchange: average expression in A group / average expression in B group. MS: mass spectrum.